SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting").
At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin and Sandy Zweifach to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:
Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
David R. Parkinson | 9,131,148 | 98.83 % | 108,123 | 1.17 % |
Richard M. Glickman | 8,823,885 | 95.50 % | 415,386 | 4.50 % |
Franklin M. Berger | 8,807,588 | 95.33 % | 431,683 | 4.67 % |
Scott Requadt | 9,130,637 | 98.82 % | 108,634 | 1.18 % |
Marella Thorell | 9,135,934 | 98.88 % | 103,337 | 1.12 % |
Alex Martin | 9,132,226 | 98.84 % | 107,045 | 1.16 % |
Sandy Zweifach | 9,112,900 | 98.63 % | 126,371 | 1.37 % |
At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; and (ii) on a non-binding advisory basis, the compensation of the Company's named executive officers.
Contact Information:
David Wood
Chief Financial Officer, ESSA Pharma Inc.
T: 778-331-0962
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
About ESSA Pharma Inc.
ESSA is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com.
| Last Trade: | US$1.86 |
| Daily Change: | 0.15 8.77 |
| Daily Volume: | 3,446,644 |
| Market Cap: | US$82.570M |
February 11, 2025 December 17, 2024 September 13, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
